Chaiyut Charoentum

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations

Sumanta K. Pal, Jonathan E. Rosenberg, Jean Hoffman‐Censits et al. · Cancer Discovery · 2018 · 257 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma

Sumitra Thongprasert, Sirikul Napapan, Chaiyut Charoentum et al. · Annals of Oncology · 2005 · 142 citations

Medicine, Oncology, Pharmacology +14

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Journal of Clinical Oncology · 2024 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Bruno Sangro, Peter R. Galle, Robin Kate Kelley et al. · Journal of Clinical Oncology · 2024 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +15